Capital expenditure · 2011–2025
Halozyme Therapeutics capital expenditure
$7.0M−34.8% · FY2025
Halozyme Therapeutics (HALO) reported $7.0M in capital expenditure for fiscal 2025, −34.8% year on year.
| Fiscal year | Capital expenditure | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $7.0M | −34.8% | Open → |
| FY20242024-12-31 | $10.7M | −30.1% | Open → |
| FY20232023-12-31 | $15.3M | +218.0% | Open → |
| FY20222022-12-31 | $4.8M | +230.1% | Open → |
| FY20212021-12-31 | $1.5M | −41.8% | Open → |
| FY20202020-12-31 | $2.5M | −38.0% | Open → |
| FY20192019-12-31 | $4.0M | −13.4% | Open → |
| FY20182018-12-31 | $4.7M | +245.4% | Open → |
| FY20172017-12-31 | $1.4M | −57.0% | Open → |
| FY20162016-12-31 | $3.1M | +32.9% | Open → |
| FY20152015-12-31 | $2.4M | +72.5% | Open → |
| FY20142014-12-31 | $1.4M | −40.4% | Open → |
| FY20132013-12-31 | $2.3M | +62.6% | Open → |
| FY20122012-12-31 | $1.4M | +70.5% | Open → |
| FY20112011-12-31 | $828,508 | — | Open → |
Capital expenditure — Capital expenditure is the cash the company spent during the year on property, plant and equipment — factories, stores, servers, vehicles. It appears in the investing section of the cash-flow statement as an outflow and is shown here as a positive amount. Operating cash flow minus this figure is free cash flow.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +16.4%
Capital expenditure at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Halozyme Therapeutics capital expenditure |url=https://companiesranked.com/en/company/halozyme-therapeutics/capital-expenditure |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Halozyme Therapeutics capital expenditure. CompaniesRanked. https://companiesranked.com/en/company/halozyme-therapeutics/capital-expenditureBibTeX
@misc{companiesranked-en-company-halozyme-therapeutics-capital-expenditure-2026,
author = {{CompaniesRanked}},
title = {{Halozyme Therapeutics capital expenditure}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/halozyme-therapeutics/capital-expenditure}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001159036-26-000024 · February 17, 2026
{{cite web |title=Halozyme Therapeutics capital expenditure — 10-K (0001159036-26-000024) |url=https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-17}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.